Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 10,406 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $15.89, for a total value of $165,351.34. Following the completion of the transaction, the chief executive officer now owns 275,526 shares in the company, valued at approximately $4,378,108.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Craig A. Wheeler also recently made the following trade(s):

  • On Tuesday, November 21st, Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.35, for a total value of $54,948.60.

Shares of Momenta Pharmaceuticals, Inc. (MNTA) opened at $16.30 on Tuesday. The stock has a market capitalization of $1,250.00, a price-to-earnings ratio of -20.38 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a 12-month low of $11.85 and a 12-month high of $19.55.

Large investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. lifted its position in shares of Momenta Pharmaceuticals by 14.9% during the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 834 shares in the last quarter. LS Investment Advisors LLC raised its position in shares of Momenta Pharmaceuticals by 59.8% in the fourth quarter. LS Investment Advisors LLC now owns 9,300 shares of the biotechnology company’s stock worth $130,000 after buying an additional 3,479 shares in the last quarter. Citigroup Inc. raised its position in shares of Momenta Pharmaceuticals by 263.2% in the second quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock worth $232,000 after buying an additional 9,954 shares in the last quarter. Piedmont Investment Advisors LLC purchased a new stake in shares of Momenta Pharmaceuticals in the second quarter worth $244,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Momenta Pharmaceuticals in the second quarter worth $247,000. Hedge funds and other institutional investors own 93.01% of the company’s stock.

MNTA has been the topic of several research analyst reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Cowen set a $15.00 target price on Momenta Pharmaceuticals and gave the stock a “hold” rating in a research report on Wednesday, November 1st. Finally, Stifel Nicolaus restated a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a research report on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. Momenta Pharmaceuticals currently has an average rating of “Hold” and an average price target of $15.30.

COPYRIGHT VIOLATION WARNING: “Craig A. Wheeler Sells 10,406 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://theolympiareport.com/2018/02/13/craig-a-wheeler-sells-10406-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.